Promising combo for cervical cancer hits roadblock: trial ends early

NCT ID NCT00421096

Terminated Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a new treatment sequence for stage IB2 to IVA cervical cancer. Patients received a combination of gemcitabine and cisplatin chemotherapy along with radiation, followed by more gemcitabine. The goal was to see if this approach could improve progression-free survival. Only 19 people enrolled before the study was terminated, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gemcitabine and cisplatin chemotherapy plus radiotherapy
What this could lead to: If successful, this could point toward a more effective treatment sequence for advanced cervical cancer.
What could go wrong: This was a small, early-phase trial that was terminated, so results are limited and may not be reliable. The combination also carries risks like low blood cell counts and organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UTERINE CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UTERINE CERVICAL CANCER

Contacts and locations

Locations

Centre Leonard de Vinci

Dechy, 59187, France
Centre Oscar Lambret

Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.